Growth-stimulating phase of macrophage response to activation : the phenomenon and its implications for tumour growth and immunotherapy
The dynamics of growth-stimulating and cytotoxic activity of mouse peritoneal macrophages (PMo) in response to in vivo and in vitro bacillus Calmette-Guérin (BCG) or bestatin treatment was studied. It was shown that BCG and bestatin induce cytotoxicity in PMo, and that after the cytotoxic response s...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 1992-07, Vol.118 (7), p.537-541 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 541 |
|---|---|
| container_issue | 7 |
| container_start_page | 537 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 118 |
| creator | OKULOV, V. B VOYTENKOV, B. O USHMOROV, A. G POLISCHUK, N. D GROMOV, S. A |
| description | The dynamics of growth-stimulating and cytotoxic activity of mouse peritoneal macrophages (PMo) in response to in vivo and in vitro bacillus Calmette-Guérin (BCG) or bestatin treatment was studied. It was shown that BCG and bestatin induce cytotoxicity in PMo, and that after the cytotoxic response strong growth-stimulating activity develops. PMo, rendered cytotoxic in vivo and afterwards cultivated in vitro, displayed the same switch from a cytotoxic to a growth-stimulating phase. These results suggest that the growth-stimulating phase is the obligatory PMo response to biological response modifiers (BRM) at least to BCG and bestatin. The growth rate of tumours, transplanted into mice during the cytotoxic phase of the response to BCG, was suppressed, whereas tumours transplanted during the growth-stimulating phase were stimulated. It appears that the development of a growth-stimulating phase after the cytotoxic phase of response to activation by BRM could be one of the reasons for the limited effectiveness of immunotherapy based on the application of macrophage activators. |
| doi_str_mv | 10.1007/BF01225269 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF01225269</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73045357</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-d1982e455e3c220ff760b3cc84e9a37e7e8083a9857d3140f5084f9d83a56c503</originalsourceid><addsrcrecordid>eNpFkE1LxDAQhoMoun5cvAs5iAehms-m9abiqiB40XOJabIbaZKapIq_wL9tdBc9DMPMPO878AJwiNEZRkicX80RJoSTut0AM8woqTClfBPMEBa44gTXO2A3pVdUZi7INtjGNWGc8Rn4uo3hIy-rlK2bBpmtX8BxKZOGwUAnVQxlWmgYdRqDL-scoFTZvhc0eHgB81IXgfbBlfJQ-h7anKB142DVL5SgCRHmyYUpwsXvuxXm3ORD0Uc5fu6DLSOHpA_WfQ88z2-eru-qh8fb--vLh0pRjHPV47YhmnGuqSIEGSNq9EKVaphuJRVa6AY1VLYNFz3FDBmOGmbavux4rTiie-Bk5TvG8DbplDtnk9LDIL0OU-oERYxTLgp4ugJLBClFbboxWifjZ4dR95N69596gY_WrtOL0_0_uoq53I_Xd5mUHEyUXtn0h_EaMUEb-g3LdYte</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73045357</pqid></control><display><type>article</type><title>Growth-stimulating phase of macrophage response to activation : the phenomenon and its implications for tumour growth and immunotherapy</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>OKULOV, V. B ; VOYTENKOV, B. O ; USHMOROV, A. G ; POLISCHUK, N. D ; GROMOV, S. A</creator><creatorcontrib>OKULOV, V. B ; VOYTENKOV, B. O ; USHMOROV, A. G ; POLISCHUK, N. D ; GROMOV, S. A</creatorcontrib><description>The dynamics of growth-stimulating and cytotoxic activity of mouse peritoneal macrophages (PMo) in response to in vivo and in vitro bacillus Calmette-Guérin (BCG) or bestatin treatment was studied. It was shown that BCG and bestatin induce cytotoxicity in PMo, and that after the cytotoxic response strong growth-stimulating activity develops. PMo, rendered cytotoxic in vivo and afterwards cultivated in vitro, displayed the same switch from a cytotoxic to a growth-stimulating phase. These results suggest that the growth-stimulating phase is the obligatory PMo response to biological response modifiers (BRM) at least to BCG and bestatin. The growth rate of tumours, transplanted into mice during the cytotoxic phase of the response to BCG, was suppressed, whereas tumours transplanted during the growth-stimulating phase were stimulated. It appears that the development of a growth-stimulating phase after the cytotoxic phase of response to activation by BRM could be one of the reasons for the limited effectiveness of immunotherapy based on the application of macrophage activators.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/BF01225269</identifier><identifier>PMID: 1624545</identifier><identifier>CODEN: JCROD7</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Animals ; Antibiotics, Antineoplastic - therapeutic use ; Antineoplastic agents ; BCG Vaccine - therapeutic use ; Biological and medical sciences ; Cell Division - drug effects ; Cytotoxicity, Immunologic - drug effects ; Female ; Fibroblasts - drug effects ; Immunologic Factors - therapeutic use ; Immunotherapy ; In Vitro Techniques ; Leucine - analogs & derivatives ; Leucine - therapeutic use ; Macrophage Activation - drug effects ; Macrophage Activation - physiology ; Medical sciences ; Mice ; Mice, Inbred C57BL ; Neoplasm Transplantation ; Neoplasms, Experimental - immunology ; Neoplasms, Experimental - pathology ; Neoplasms, Experimental - therapy ; Pharmacology. Drug treatments</subject><ispartof>Journal of cancer research and clinical oncology, 1992-07, Vol.118 (7), p.537-541</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-d1982e455e3c220ff760b3cc84e9a37e7e8083a9857d3140f5084f9d83a56c503</citedby><cites>FETCH-LOGICAL-c311t-d1982e455e3c220ff760b3cc84e9a37e7e8083a9857d3140f5084f9d83a56c503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5604738$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1624545$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OKULOV, V. B</creatorcontrib><creatorcontrib>VOYTENKOV, B. O</creatorcontrib><creatorcontrib>USHMOROV, A. G</creatorcontrib><creatorcontrib>POLISCHUK, N. D</creatorcontrib><creatorcontrib>GROMOV, S. A</creatorcontrib><title>Growth-stimulating phase of macrophage response to activation : the phenomenon and its implications for tumour growth and immunotherapy</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><description>The dynamics of growth-stimulating and cytotoxic activity of mouse peritoneal macrophages (PMo) in response to in vivo and in vitro bacillus Calmette-Guérin (BCG) or bestatin treatment was studied. It was shown that BCG and bestatin induce cytotoxicity in PMo, and that after the cytotoxic response strong growth-stimulating activity develops. PMo, rendered cytotoxic in vivo and afterwards cultivated in vitro, displayed the same switch from a cytotoxic to a growth-stimulating phase. These results suggest that the growth-stimulating phase is the obligatory PMo response to biological response modifiers (BRM) at least to BCG and bestatin. The growth rate of tumours, transplanted into mice during the cytotoxic phase of the response to BCG, was suppressed, whereas tumours transplanted during the growth-stimulating phase were stimulated. It appears that the development of a growth-stimulating phase after the cytotoxic phase of response to activation by BRM could be one of the reasons for the limited effectiveness of immunotherapy based on the application of macrophage activators.</description><subject>Animals</subject><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>Antineoplastic agents</subject><subject>BCG Vaccine - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cell Division - drug effects</subject><subject>Cytotoxicity, Immunologic - drug effects</subject><subject>Female</subject><subject>Fibroblasts - drug effects</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Immunotherapy</subject><subject>In Vitro Techniques</subject><subject>Leucine - analogs & derivatives</subject><subject>Leucine - therapeutic use</subject><subject>Macrophage Activation - drug effects</subject><subject>Macrophage Activation - physiology</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Neoplasm Transplantation</subject><subject>Neoplasms, Experimental - immunology</subject><subject>Neoplasms, Experimental - pathology</subject><subject>Neoplasms, Experimental - therapy</subject><subject>Pharmacology. Drug treatments</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LxDAQhoMoun5cvAs5iAehms-m9abiqiB40XOJabIbaZKapIq_wL9tdBc9DMPMPO878AJwiNEZRkicX80RJoSTut0AM8woqTClfBPMEBa44gTXO2A3pVdUZi7INtjGNWGc8Rn4uo3hIy-rlK2bBpmtX8BxKZOGwUAnVQxlWmgYdRqDL-scoFTZvhc0eHgB81IXgfbBlfJQ-h7anKB142DVL5SgCRHmyYUpwsXvuxXm3ORD0Uc5fu6DLSOHpA_WfQ88z2-eru-qh8fb--vLh0pRjHPV47YhmnGuqSIEGSNq9EKVaphuJRVa6AY1VLYNFz3FDBmOGmbavux4rTiie-Bk5TvG8DbplDtnk9LDIL0OU-oERYxTLgp4ugJLBClFbboxWifjZ4dR95N69596gY_WrtOL0_0_uoq53I_Xd5mUHEyUXtn0h_EaMUEb-g3LdYte</recordid><startdate>19920701</startdate><enddate>19920701</enddate><creator>OKULOV, V. B</creator><creator>VOYTENKOV, B. O</creator><creator>USHMOROV, A. G</creator><creator>POLISCHUK, N. D</creator><creator>GROMOV, S. A</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19920701</creationdate><title>Growth-stimulating phase of macrophage response to activation : the phenomenon and its implications for tumour growth and immunotherapy</title><author>OKULOV, V. B ; VOYTENKOV, B. O ; USHMOROV, A. G ; POLISCHUK, N. D ; GROMOV, S. A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-d1982e455e3c220ff760b3cc84e9a37e7e8083a9857d3140f5084f9d83a56c503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Animals</topic><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>Antineoplastic agents</topic><topic>BCG Vaccine - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cell Division - drug effects</topic><topic>Cytotoxicity, Immunologic - drug effects</topic><topic>Female</topic><topic>Fibroblasts - drug effects</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Immunotherapy</topic><topic>In Vitro Techniques</topic><topic>Leucine - analogs & derivatives</topic><topic>Leucine - therapeutic use</topic><topic>Macrophage Activation - drug effects</topic><topic>Macrophage Activation - physiology</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Neoplasm Transplantation</topic><topic>Neoplasms, Experimental - immunology</topic><topic>Neoplasms, Experimental - pathology</topic><topic>Neoplasms, Experimental - therapy</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OKULOV, V. B</creatorcontrib><creatorcontrib>VOYTENKOV, B. O</creatorcontrib><creatorcontrib>USHMOROV, A. G</creatorcontrib><creatorcontrib>POLISCHUK, N. D</creatorcontrib><creatorcontrib>GROMOV, S. A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OKULOV, V. B</au><au>VOYTENKOV, B. O</au><au>USHMOROV, A. G</au><au>POLISCHUK, N. D</au><au>GROMOV, S. A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Growth-stimulating phase of macrophage response to activation : the phenomenon and its implications for tumour growth and immunotherapy</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>1992-07-01</date><risdate>1992</risdate><volume>118</volume><issue>7</issue><spage>537</spage><epage>541</epage><pages>537-541</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><coden>JCROD7</coden><abstract>The dynamics of growth-stimulating and cytotoxic activity of mouse peritoneal macrophages (PMo) in response to in vivo and in vitro bacillus Calmette-Guérin (BCG) or bestatin treatment was studied. It was shown that BCG and bestatin induce cytotoxicity in PMo, and that after the cytotoxic response strong growth-stimulating activity develops. PMo, rendered cytotoxic in vivo and afterwards cultivated in vitro, displayed the same switch from a cytotoxic to a growth-stimulating phase. These results suggest that the growth-stimulating phase is the obligatory PMo response to biological response modifiers (BRM) at least to BCG and bestatin. The growth rate of tumours, transplanted into mice during the cytotoxic phase of the response to BCG, was suppressed, whereas tumours transplanted during the growth-stimulating phase were stimulated. It appears that the development of a growth-stimulating phase after the cytotoxic phase of response to activation by BRM could be one of the reasons for the limited effectiveness of immunotherapy based on the application of macrophage activators.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>1624545</pmid><doi>10.1007/BF01225269</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 1992-07, Vol.118 (7), p.537-541 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF01225269 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Animals Antibiotics, Antineoplastic - therapeutic use Antineoplastic agents BCG Vaccine - therapeutic use Biological and medical sciences Cell Division - drug effects Cytotoxicity, Immunologic - drug effects Female Fibroblasts - drug effects Immunologic Factors - therapeutic use Immunotherapy In Vitro Techniques Leucine - analogs & derivatives Leucine - therapeutic use Macrophage Activation - drug effects Macrophage Activation - physiology Medical sciences Mice Mice, Inbred C57BL Neoplasm Transplantation Neoplasms, Experimental - immunology Neoplasms, Experimental - pathology Neoplasms, Experimental - therapy Pharmacology. Drug treatments |
| title | Growth-stimulating phase of macrophage response to activation : the phenomenon and its implications for tumour growth and immunotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T20%3A46%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Growth-stimulating%20phase%20of%20macrophage%20response%20to%20activation%20:%20the%20phenomenon%20and%20its%20implications%20for%20tumour%20growth%20and%20immunotherapy&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=OKULOV,%20V.%20B&rft.date=1992-07-01&rft.volume=118&rft.issue=7&rft.spage=537&rft.epage=541&rft.pages=537-541&rft.issn=0171-5216&rft.eissn=1432-1335&rft.coden=JCROD7&rft_id=info:doi/10.1007/BF01225269&rft_dat=%3Cproquest_cross%3E73045357%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73045357&rft_id=info:pmid/1624545&rfr_iscdi=true |